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 Does reducing salt intake increase 
cardiovascular mortality ? 
 Feng J.  He 1 ,  Lawrence J.  Appel 2 ,  Francesco P.  Cappuccio 3 ,  
Hugh E.  de Wardener 4 and  Graham A.  MacGregor 1 
 Overwhelming evidence shows that reducing salt intake from 9 – 12 
to 5 – 6  g / d lowers blood pressure, thereby preventing cardiovascular 
disease. A recent paper claims that lower salt intake is associated with 
higher cardiovascular mortality despite lower blood pressure. The study 
is flawed and cannot refute the evidence for the benefits of salt 
reduction. The WHO recommends salt reduction as crucial in tackling 
the global non-communicable-disease crisis. A reduction in population 
salt intake remains a public-health priority. 
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 Th ere is much evidence that raised blood 
pressure (BP) throughout its range (that 
is, starting at 115 / 75  mm  Hg) is a major 
cause of cardiovascular disease (CVD) 1 —
 strokes, heart attacks, heart failure, and 
renal disease. A modest reduction in salt 
intake lowers BP and, therefore, would 
reduce CVD. Indeed, both prospective 
cohort studies and outcome trials have 
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demonstrated that a lower salt intake is 
related to a reduced risk of CVD. 2,3 Over 
the past few years, this evidence has been 
repeatedly reviewed by several independ-
ent national and international panels of 
experts around the world. All have 
reached the same conclusions and devel-
oped recommendations for a popula-
tion-wide reduction in salt intake to 
prevent CVD. 4 – 7 
 Contrary to the above, a recent study by 
Stolarz-Skrzypek  et al. in the  Journal of the 
American Medical Association claimed 
that  ‘ lower sodium excretion was associ-
ated with higher CVD mortality. ’ 8  Detailed 
examination of this  study, however, reveals 
many serious flaws. Most importantly, 
there are substantial concerns related to 
the collection of 24-h urine specimens, 
leading to misclassifi cation and bias. Th is 
is a common problem in cohort studies 
with paradoxical fi ndings. 9 – 11 Specifi cally, 
individuals in the lowest tertile of 24-h 
urinary sodium also had lower 24-h urine 
volume, lower potassium, and lower cre-
atinine excretion. Th is pattern of fi ndings 
clearly indicates an undercollection of 
24-h urine that could not be fully 
explained by a lower body weight. 
 Further support for undercollection of 
24-h urine is evident in the methods sec-
tion, where it is reported that  ‘ participants 
collected an exactly timed 24-h urine sam-
ple in a 2500  ml wide-neck plastic con-
tainer. ’ 8 It appears that only one 2.5-liter 
container was provided to the partici-
pants, which is not large enough for indi-
viduals who drink more fl uid. Th is would 
lead to undercollection of urine in these 
people. Th e standard practice is to give a 
5-liter container to adults and a 2.5-liter 
container to children. Taken together, 
these issues suggest that many of the indi-
viduals in the lowest sodium-excretion 
tertile were likely misclassifi ed because 
they did not properly collect a full 
24-h urine. 
 Nonadherence to instructions could 
also have played a role. If individuals 
could not collect their urine properly, they 
may be less compliant with BP or other 
treatments. It is therefore not surprising 
that they may have a higher CVD mortal-
ity, given that they also had higher cardio-
vascular risk factor levels — the lowest 
level of educational attainment, higher 
baseline systolic BP, higher total choles-
terol levels, and a higher prevalence of 
smoking. 8 An association of increased 
mortality with low urinary sodium excre-
tion was also reported in a cohort of dia-
betics, but the levels of urinary sodium 
excretion were biologically implausible, 
as low as 20  mmol / d, consistent with 
undercollection. In this study, the nearly 
20-fold increased risk of mortality was 
most likely due to noncompliance with 
collection procedures. 10 Overall, incom-
plete collection of 24-h urine in cohort 
studies refl ects poor adherence to data 
collection procedures and is similar con-
ceptually to nonadherence in clinical 
trials, where it is well documented that 
nonadherence, even to placebo, is associ-
ated with high mortality rates. 12 Th ese 
fundamental errors in collecting complete 
24-h urine invalidate the results of the 
study by Stolarz-Skrzypek  et al. 8 
see  JAMA 2011; 305: 1777 – 1785
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 A second issue is the small number of 
CVD deaths, probably due to the young 
age of the participants studied. A total of 
3681 participants with an average age of 
about 40 years were followed up for a 
median 7.9 years. 8 Th e number of CVD 
deaths according to tertiles of baseline 24-h 
urinary sodium excretion was 50 in the 
low (mean, 107  mmol), 24 in the medium 
(168  mmol), and 10 in the high excretion 
group (260  mmol). Stolarz-Skrzypek 
 et al. 8 compared the risk for each of these 
three groups with the risk for all three 
groups together. Such analysis is strange, 
as the usual practice for this type of study 
is to compare each group with a reference 
group. It is unclear why Stolarz-Skrzypek 
 et al. 8 used such a method;  presumably 
they did so because the number of CVD 
deaths in each group (for example,  N  =  10) 
is too small for valid statistical compari-
sons. In view of this odd analysis, we 
assume that a direct comparison between 
the high and low tertiles or between the 
medium and low tertiles was not signifi -
cant. It is extraordinary that, on the basis 
of such a small number of CVD deaths 
and one 24-h urinary sodium measured 
about 8 years earlier, the authors con-
cluded that  ‘ our current fi ndings refute the 
estimates of computer models of lives 
saved and health care costs reduced with 
lower salt intake. ’ 8 
 Third, Stolarz-Skrzypek  et al. 8 also 
reported a separate  ‘ blood pressure cohort ’ 
of 1499 participants who were followed up 
for 6.1 years and in whom 24-h urinary 
sodium measurement was repeated at the 
end of follow-up. Th is analysis showed 
a signifi cant relationship between 24-h 
urinary sodium and systolic BP, with a 
100-mmol increase in sodium excretion 
associated with a 1.71-mm  Hg increase in 
systolic BP ( P  <  0.001). 8 Importantly, the 
authors did not mention whether BP pre-
dicted cardiovascular mortality. If not, 
there would be a fundamental problem 
with the study, as they would have to 
claim, on the basis of their reasoning 
about salt, that BP is not a determinant of 
cardiovascular events. 
 Stolarz-Skrzypek  et al. 8 tried to ascribe 
the higher CVD mortality with a lower 
salt intake to the activation of the renin –
 angiotensin – aldosterone system and the 
sympathetic nervous system, as well as a 
decrease in insulin sensitivity. Th ey cited 
the meta-analysis by Graudal  et al. 13 as the 
evidence for these claims. However, this 
meta-analysis included a very large 
number of trials with conditions ranging 
from acute salt loading to abrupt and 
severe salt restriction — for example, from 
20 to less than 1  g / d for only a few days. 
Such acute salt loading and depletion 
experiments are not relevant to public-
health recommendations for a modest 
reduction in salt intake for a prolonged 
period of time. Indeed, randomized trials 
have demonstrated that, with a longer-
term modest reduction in salt intake, there 
was only a small increase in plasma renin 
activity, 14 and no substantial change in the 
sympathetic nervous activity, 15 glucose 
tolerance, or insulin sensitivity. 16 Stolarz-
Skrzypek  et al. 8 failed to cite these more 
relevant papers. 
 Furthermore, salt reduction lowers BP 
by a similar mechanism to that of thi-
azide diuretics. Both stimulate the renin – 
angiotensin system and, in the short 
term, the sympathetic nervous system. 
However, outcome trials have demon-
strated that thiazide diuretics signifi-
cantly reduced cardiovascular morbidity 
and mortality in hypertensive individu-
als. 17 It could be argued that long-term 
treatment with thiazide diuretics may 
increase the risk of diabetes. 18 However, 
this is likely to be due to the lower serum 
potassium that occurred. 18 Concomitant 
treatment with potassium supplementa-
tion or use of potassium-sparing diuret-
ics has been shown to lessen the glucose 
intolerance and possibly prevent the 
development of thiazide-induced diabe-
tes. 18 Th e advantage of modest salt reduc-
tion over thiazide diuretics is that salt 
reduction does not have a significant 
eff ect on serum potassium but has a sim-
ilar BP-lowering eff ect in hypertensive 
individuals, as demonstrated by ran-
domized trials. 19 
 Finally, there are several additional 
problems with the study by Stolarz-
Skrzypek  et al. 8 A large number of par-
ticipants had missing or incomplete data 
or were lost to follow-up. Th e presentation 
of results was also confusing. For example, 
one cohort was analyzed as three separate 
cohorts with diff erent eligibility criteria, 
diff erent numbers of participants, and dif-
ferent durations of follow-up. Th is confus-
ing presentation makes it extremely 
diffi  cult to judge the validity of the study 
methodology. Th e study also has other 
paradoxical results. Th e fi nding of low 
urinary potassium in those excreting low 
sodium is unanticipated, as the major 
mechanism for marked reduction in 
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 Figure 1  |  Cumulative incidence of cardiovascular disease (CVD) by salt intervention group in the Trial of Hypertension Prevention (TOHP) I 
and II, adjusted for age, sex, and clinic. Adapted from Cook  et al . 3 
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sodium intake is the eating of unprocessed 
foods, which are high in potassium. Th e 
presence of low potassium excretion in 
the group with low sodium excretion, 
therefore, suggests either substantive 
residual confounding possibly due to 
overall food intake and poverty or nonad-
herence to the urine collection procedure, 
as previously noted. Another paradoxical 
fi nding is the  ‘ inverse ’ association between 
urinary sodium-to-potassium ratio and 
CVD outcomes, a fi nding at variance with 
the vast majority of population studies 
reported so far. 
 Because of the serious fl aws described 
above, the study by Stolarz-Skrzypek 
 et al. 8 cannot be used to refute the strong 
evidence that a modest reduction in pop-
ulation salt intake is extremely benefi cial 
to health and could prevent millions of 
deaths from strokes, heart attacks, heart 
failure, and kidney disease each year. 4 – 7,20 
A meta-analysis of all prospective cohort 
studies has demonstrated a direct relation-
ship between salt intake, stroke, and CVD 
risk. 2 Th is association remained signifi -
cant even when the study by Stolarz-
Skrzypek  et al. was included in an updated 
meta-analysis. Th e pooled results showed 
that an increase of approximately 5  g / d in 
salt intake (that is, 2  g / d or 85  mmol / d of 
sodium) was related to a 20 % increase in 
the risk of stroke ( P  =  0.026) and a 14 % 
increase in total CVD ( P  =  0.07). Stronger 
evidence comes from outcome trials. 3,21 
A follow-up study of individuals who took 
part in two large randomized salt reduc-
tion trials demonstrated that a 25 – 30 % 
reduction in salt intake resulted in a 
25 % decrease in cardiovascular events 
( Figure 1 ). 3 Another outcome trial of 
more than 2.5 years in elderly Taiwanese 
veterans ( N   =  1981) showed that switch-
ing from the usual salt (sodium chloride) 
to potassium-enriched salt (49 % sodium 
chloride, 49 % potassium chloride, 2 % 
other additives) with a subsequent reduc-
tion of 17 % in salt intake and an increase 
of 76 % in potassium intake resulted in a 
40 % decrease in CVD mortality. 21 
 In conclusion, the totality of the evi-
dence for a causal relationship of chronic 
high salt intake with elevated BP and CVD 
is robust and persuasive. 4 – 7,20 Th e paper 
by Stolarz-Skrzypek  et al. 8 and other 
papers 9 – 11 with paradoxical findings 
related to methodologic fl aws should not 
divert us from reducing salt intake world-
wide. A reduction in salt from the current 
intake of 9 – 12  g / d to the recommended 
level of less than 5 – 6  g / d will have major 
beneficial effects on health along with 
major cost savings in all countries around 
the world. 4 – 7,20 At a recent high-level 
policy meeting of the World Health 
Organization, salt reduction has been rec-
ommended as one of the top priority 
actions to tackle the global non-commu-
nicable-disease crisis. 22,23 Rather than 
pursuing the question of  whether salt 
intake should be reduced to prevent CVD, 
the global health priority is and should 
remain  how to reduce population salt 
intake to save lives. 
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